Skip to content
Home/Companies/Biotech/AgomAb Therapeutics
AT

AgomAb Therapeutics

Biotech·Belgium·Exited 2026·Held 7yr

Agomab Therapeutics is a healthcare company, headquartered in Belgium.

Entry
2019
Hold
7yr
Exit
2026
Est. EV
–

Who owns AgomAb Therapeutics?

AgomAb Therapeutics was owned by Omnes Capital through Omnes Real Tech 1 (2018 vintage) from 2019 to 2026, exited via IPO. Across its history, AgomAb Therapeutics has been through 2 private equity ownership periods, detailed in the timeline below.

Hand-verified · updated 2026-04-21

Omnes Capital
Most recent investor
Omnes Capital
Omnes Real Tech 1 · 2018 · VC
2 ownership periods · full history below

Key facts

HQBelgium
SectorHealthcare
Key takeaways
  • ·Fully exited in 2026.
  • ·Average hold across 2 realized cycles: 7 years.

Ownership history

2 ownership periods · co-invest detected

Exited
Last exited in 2026.
Co-invest · 2 holders · 2019 · 2026
AdBio Partners
AdBio PartnersExited 2026
2019 · 2026 · AFB Seed-Fund · 2017 · VC
IPO · to
MOIC
–
Omnes Capital
Omnes CapitalExited 2026
2019 · 2026 · Omnes Real Tech 1 · 2018 · VC
IPO
MOIC
–

More from Omnes Real Tech 1

Other portfolio companies in the same fund.

DiogenX
Active
BiotechFrance· 2023
Jimmy Energy
Active
ClimateTechFrance· 2023
Planet A Foods
Active
BiotechGermany· 2023
Quantum Systems
Active
Aerospace & DefenceGermany· 2023
IKTOS
Active
BiotechFrance· 2022
Lithosquare
Active
IndustrialsFrance· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings